Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Cost Reimbursement

Drugs

Locations

Clinical Specialty

501-520 of 991 trials

Multiple Myeloma: Teclistamab with Lenalidomide

We are studying a new treatment combining teclistamab and lenalidomide for patients with newly diagnosed multiple myeloma after stem cell transplant. The aim is to see if this combination works better than lenalidomide alone in maintaining remission.

Newly Diagnosed Multiple MyelomaConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyOncology

Cirrhosis Treatment: Pegozafermin Study

We are studying a new medication, pegozafermin, for individuals with compensated cirrhosis due to MASH. The goal is to see if it can improve liver health and reduce related health risks compared to a placebo.

Chronic Liver Disease and Cirrhosis>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteEndocrinologyHepatology

Brivaracetam for Childhood Absence Epilepsy

We are studying whether brivaracetam is effective and safe for children and young adults aged 2 to 25 with childhood or juvenile absence epilepsy. This trial aims to provide insights into its use as a standalone treatment.

Childhood Absence Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)6-10 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

HER2-Altered Cancers: Zongertinib Study

We are testing whether zongertinib can help people with advanced solid tumors that have HER2 mutations or overexpression. The study will evaluate its effectiveness, safety, and how patients respond to the treatment.

HER2-mutated or overexpressed/amplified solid tumorsEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Septic Shock: Levetiracetam Treatment Study

We are studying whether early treatment with levetiracetam can help patients with septic shock stay awake and alert. The trial also examines its effects on survival and overall quality of life.

Septic Shock>2 yearsConfirmation phase (III)Standard Medicines Cost Reimbursement Partially RemoteInfectious DiseasesInternal MedicineNeurologyPulmonology

Pancreatic Cancer: SGM-101 Imaging Study

We are testing a new imaging agent to help surgeons better see pancreatic tumors during surgery. This study aims to improve the accuracy of tumor detection and assess the extent of cancer in patients who have received prior treatment.

Pancreatic Tumor3-6 monthsEfficacy phase (II)≤5 visits No Placebo Investigational Medicines Cost ReimbursementGastroenterologyInternal MedicineOncology

Crohn's Disease: AZD7798 Treatment Study

We are investigating how well AZD7798 works and its safety for people with moderate to severe Crohn's disease. This study will help us understand its effects on disease activity and overall health.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterology

Psilocybin Therapy for Depression in Serious Illnesses

We are studying whether medium/high doses of psilocybin can help reduce depression and anxiety in patients with COPD, ALS, MS, or APD. This research aims to improve their quality of life and support their caregivers.

Chronic Respiratory and Neurological Disorders≤3 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemotePsychiatryPulmonology

Acute Myeloid Leukemia: KO-539 Treatment Study

We are testing a new drug called KO-539 in patients with relapsed or refractory acute myeloid leukemia. The goal is to see if it is safe and effective for those with specific genetic mutations.

Relapsed Acute Myeloid Leukemia≤3 monthsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

ANCA-Associated Vasculitis: LNP023 (iptacopan) Study

We are testing a new treatment for patients with active ANCA-associated vasculitis to see if it helps achieve lasting remission compared to standard care. The study will also evaluate its impact on disease relapse and kidney health.

Microscopic PolyangiitisGranulomatosis with Polyangiitis1-2 yearsEfficacy phase (II)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Non-Alcoholic Steatohepatitis: Namodenoson Study

We are testing a new oral medication, namodenoson, for individuals with Non-Alcoholic Steatohepatitis (NASH). The study aims to see if it improves liver health and to evaluate its safety.

Non-Alcoholic Steatohepatitis (NASH)6-12 monthsEfficacy phase (II)6-10 visits Investigational Medicines Cost ReimbursementHepatologyInternal Medicine

Head and Neck Cancer: New Treatment Combinations

We are comparing a new drug combination with a single drug for patients with locally advanced head and neck cancer. The aim is to see which treatment works better before starting chemoradiotherapy.

Locally Advanced Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No Placebo Investigational Medicines Cost ReimbursementOncology

Systemic Lupus Erythematosus: Obexelimab Study

We are studying a new medication, Obexelimab, for patients with systemic lupus erythematosus to see if it can lower disease activity and reduce fatigue. This trial compares its effects to a placebo treatment.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementInternal MedicineRheumatology

Intranasal COVID-19 Vaccine: LVT-001

We are studying a new intranasal booster vaccine for COVID-19 to see if it is safe and more effective than the standard mRNA vaccine. This trial is for healthy adults who want to help improve COVID-19 vaccination strategies.

COVID-191-2 yearsSafety phase (I)Efficacy phase (II)6-10 visits No Placebo Investigational Medicines Cost ReimbursementInfectious Diseases

Parkinson's Disease: New Approaches to Levodopa Resistance

We are studying whether the medication apomorphine or the antibiotic rifaximin can help people with Parkinson's disease who struggle with levodopa treatment. This trial aims to improve their symptoms and overall treatment response.

Parkinson's Disease6-12 monthsEfficacy phase (II)≤5 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementInternal MedicineNeurology

Advanced Solid Tumors: BT5528 Treatment Study

We are testing a new drug, BT5528, for patients with advanced solid tumors that express EphA2. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Chronic Migraine: Eptinezumab for Teens

We are studying whether eptinezumab can help reduce the number of migraine days in adolescents aged 12 to 17 with chronic migraine. This trial compares the medication to a placebo to assess its effectiveness.

Migraine3-6 monthsConfirmation phase (III)≤5 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Zanamivir for Infants with Complicated Influenza

We are studying how safe and effective intravenous zanamivir is for hospitalized infants under 6 months with complicated influenza. This research aims to understand how the drug works in young children.

Human Influenza>2 yearsEfficacy phase (II)≤5 visits No Placebo Standard Medicines Cost ReimbursementInfectious DiseasesPediatrics

DAY101 for Pediatric Brain Cancer and Solid Tumors

We are studying the effects of DAY101 in children aged 6 months to 25 years with low-grade glioma or advanced solid tumors. The goal is to see if it helps shrink tumors and to assess its safety.

Malignant Glioma>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncologyPediatrics

Mpox Booster Vaccine: Fractional vs. Full Dose

We are studying whether a smaller booster dose of the MVA-BN vaccine is as effective as the standard dose in adults. This trial will also look at the safety and immune response of both doses.

Mpox (Monkeypox)3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visits No Placebo Standard Medicines Cost ReimbursementInfectious Diseases

Search Clinical Trials in the European Union